KOHLI-VENTURES
10.6.2019 10:02:18 CEST | Business Wire | Press release
At London Tech Week: Tej Kohli, the London-based tech entrepreneur, has invested another $100m into Rewired, a robotics-focused venture studio with a humanitarian bent. Rewired is pioneering investment into artificial intelligence and machine learning ventures that will power the new economy, transform businesses, revolutionise global healthcare and even improve and extend human life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005161/en/
Some of the companies already backed by Rewired include:
- Open Bionics: is developing the next generation of prosthetics, which for the first time enable patients to feel their surrounding environment through their prosthesis.
- Aromyx: is developing technologies that for the first time enable scientifically reproducible measurement and digitisation of taste and scent. Applications include the detection and capture of new data modalities for machine learning.
- Seldon: has developed the world’s first open source machine learning platform to enable data scientists, developers and large organisations to share data, thus harnessing the network effect for machine learning and enabling machines to learn faster, bigger and better.
Current thinking suggests that the global AI market will be worth anything from $3.9 trillion by 2022 (Gartner) to $15.7 trillion by 2030 (PWC) – but Tej Kohli believes that the true value could be much greater.
Kohli commented:
“Conventional wisdom is too cautious. I predict that the global AI sector will be worth $150 trillion by 2025. My forecast is based on a five-part analysis:
- The Internet today is worth $50 trillion. You can take that and extrapolate it to at least three or four times as many applications as the Internet to get $150 trillion. I don’t see how it can be any less because AI has so many different industries and applications;
- Everything that is currently on the Internet can also be manifested through AI in smarter and better and more effective ways. These Internet-linked applications alone are worth hundreds of billions – and AI can be similarly applied across hundreds of other industries;
- The rapid pace of growth of AI in China, with Shenzen now a global hub of AI excellence that will surpass the ever more regulated Silicon Valley in the medium term;
- The global growth in 5G coverage plus ubiquitous smartphone usage removing technological barriers to embracing the AI revolution in a true Internet of Things;
- That we are now at a tipping point, after which AI and machine learning will grow exponentially to underpin and benefit every single aspect of human life.
“I am not saying that $150 trillion is based on a complete adoption of AI across everything. I believe $150 trillion is where you get to when keeping our basic human norms and values intact. It is using AI to make our lives more efficient without radically changing our lives to the full extent that AI is capable of. I estimate this value to be three to four times the Internet.
“And I believe that AI will enable humanity to take unprecedented leaps forward in solving the most pressing human problems across poverty, geopolitics and unequal access to healthcare, by virtue of its ability to make businesses and organisations far more efficient. There is scope for huge commercial gain coupled with unprecedented opportunities for human progress.”
About Tej Kohli
Tej Kohli is a London-based technology and real estate entrepreneur, businessman and philanthropist who now focuses on visionary ventures and investments that have the potential to transform lives and change the world. Through his investment vehicle Kohli Ventures, Mr Kohli targets high-impact investments into AI, robotics, biotech, genomics and Fintech that help to solve the world’s most pressing challenges and create a better tomorrow.
Mr Kohli also has a well-publicized mission to cure corneal blindness worldwide by 2030 through the philanthropic Tej Kohli Foundation that provides direct funding for the Tej Kohli Cornea Institute, a preeminent global institute for solving corneal blindness worldwide.
Mr Kohli is a Distinguished Alumnus of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering. He first rose to success building innovative white label technology and e-commerce solutions for companies during the dot com boom.
About Rewired
Rewired is a robotics-focused venture studio specializing in applied science and technologies. Rewired launched in 2017 with an initial $100 million fund for technologies that will enable robots to interact properly with real-world environments. In backing the development of robots’ sensory capabilities and understanding of the world around them, Rewired seeks to play a major part in enabling the safe and efficient integration of machine learning into everyday life.
For more information about Rewired see https://youtu.be/6yc5EcBIU5U
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005161/en/
Contact:
For an interview with Tej Kohli please contact: Mike Macfarlane mike@kohliventures.com +447764 225 924
Helen Tarbet / Kim van Beeck / Hannah Ratcliff (Buchanan) kohliventures@buchanan.uk.com +4420 7466 5000
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
